<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466137</url>
  </required_header>
  <id_info>
    <org_study_id>TB1801CSF</org_study_id>
    <nct_id>NCT04466137</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy</brief_title>
  <official_title>A Multi-centers, Randomized, Open-labeled, Positive-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF, Once-per-cycle, in Patients With Malignancies Receiving Myelosuppressive Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing
      the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who
      receiving Myelosuppressive Chemotherapy which is likely to cause clinically significant
      febrile neutropenia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Duration of Severe Neutropenia (DSN) During Cycle 1.</measure>
    <time_frame>At the end of Cycle 1 (21 days one cycle)</time_frame>
    <description>Mean duration of severe neutropenia, defined as number of consecutive days with absolute neutrophil count (ANC) &lt;0.5 × 10^9 cells/l (grade 4 neutropenia)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Febrile neutropenia(FN).</measure>
    <time_frame>Cycle1 to Cycle 4(21 days one cycle)</time_frame>
    <description>FN defines as the ANC counts is less than &lt; 0.5 × 10^9 cells/L or ANC counts between 0.5 × 10^9 cells/L and 1.0 × 10^9 cells/L but probably to decline to less than 0.5×10^9 cells/L within 48hrs, and body temperature is higher than 38.3 degrees Celsius or higher than 38.0 degrees Celsius and lasting for more than 1hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of DSN.</measure>
    <time_frame>Cycle2 to Cycle 4 (21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 neutropenia.</measure>
    <time_frame>Cycle1 to Cycle 4 ( 21 days one cycle)</time_frame>
    <description>Grade 3 neutropenia defines as the ANC count is less than 1.0×10^9 cells/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of grade 3 neutropenia.</measure>
    <time_frame>Cycle1 to Cycle 4(21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils dynamic changes from baseline.</measure>
    <time_frame>Cycle1 to Cycle 4 ( 21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of neutrophils recovering to over 2.0×10^9 cells/L after nadir.</measure>
    <time_frame>Cycle1 to Cycle 4 (21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with antibiotic usage.</measure>
    <time_frame>Cycle1 to Cycle 4 ( 21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experienced infection.</measure>
    <time_frame>Cycle1 to Cycle 4 ( 21 days one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients fulfilling expected chemotherapy.</measure>
    <time_frame>Cycle1 to Cycle 4 (21 days one cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Non-Myeloid Malignancy</condition>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YPEG-rhG-CSF 2mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 33μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YPEG-rhG-CSF 33μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rhG-CSF/PEG-rhG-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF</intervention_name>
    <description>YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.</description>
    <arm_group_label>YPEG-rhG-CSF 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF</intervention_name>
    <description>YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.</description>
    <arm_group_label>YPEG-rhG-CSF 33μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF/PEG-rhG-CSF</intervention_name>
    <description>rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.</description>
    <arm_group_label>Positive Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathology and/or cytology diagnosed as breast cancer (BC) or non-small cell lung
             cancer (NSCLC), and patients with breast cancer is suitable to receive
             TAC(Docetaxel,Doxorubicin combined with Cyclophosphamide) chemotherapy, while patients
             with NSCLC is suitable to receive DC(Docetaxel combined with Carboplatin)
             chemotherapy.

          -  Age ≥18 yrs.

          -  Weight ≥45 kg.

          -  Karnofsky Score ≥ 70.

          -  Life Expectancy ≥ 3 months.

          -  Peripheral blood test: WBC≥3.5×10^9 cells/L, PLT≥100×10^9 cells/L. ANC≥1.5×10^9
             cells/L.

          -  Understand and voluntarily sign the informed consent form.

        Exclusion Criteria:

          -  Receiving chemotherapy within two months prior to screening.

          -  Previously or plan to receive radiotherapy (&gt;25% total bone marrow volume).

          -  Evidence of tumor metastasis in bone marrow.

          -  Lack of awareness.

          -  Uncontrolled infection or using of antibiotics within 72hrs prior to screening.

          -  Previously received or plan to undergoing bone marrow or organ transplants.

          -  Patients with bleeding tendency, e.g. prolonged prothrombin time of more than 3
             seconds.

          -  Dysfunction in heart,lung, liver, kidney, or other major organs or systems; ALT&gt;2.5
             ULN (upper limit of normal), TBil &gt;2.5 ULN (ALT&gt;2.5 ULN, total bilirubin &gt;2.5 ULN for
             patients with liver metastasis), HBsAg positive, anti-HCV positive, evidence of liver
             decompensation, or Cr &gt;1.5 ULN.

          -  Pregnant or lactating females.

          -  Malignancy other than BC or NSCLC.

          -  Hypersensitivity to rhG-CSF or any component of the investigational Products.

          -  Subject enrolled in any other studies within 3 months prior to screening.

          -  Drug abuser or alcoholics.

          -  Any other conditions which in the opinion of the investigator precluded enrollment
             into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Yi</last_name>
    <phone>0592-6889121</phone>
    <email>yixiaoyan@amoytop.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shengyu Zhou, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>G-CSF</keyword>
  <keyword>Human Granulocyte Colony-Stimulating Factor</keyword>
  <keyword>Febrile Neutropenia</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Myelosuppressive Chemotherapy</keyword>
  <keyword>FN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

